anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chysobalanus icaco L. (C. icaco) is a plant that is native to tropical America and Africa. It is also found in the southeast region of Mexico, where it is used as food and to treat certain diseases. This study aimed to carry out a phytochemical analysis of an aqueous extract of C. icaco seed (AECS), including its total phenol content (TPC), total flavonoid content (TFC), and condensed tannins (CT). It also aimed to examine the antioxidant and metal-ion-reducing potential of the AECS in vitro, as well as its toxicity and anti-inflammatory effect in mice. Antioxidant and metal-ion-reducing potential was examined by inhibiting DPPH, ABTS, and FRAP. The acute toxicity test involved a single administration of different doses of the AECS (0.5, 1, and 2 g/kg body weight). Finally, a single administration at doses of 150, 300, and 600 mg/kg of the AECS was used in the carrageenan-induced model of subplantar acute edema. The results showed that the AECS contained 124.14 ± 0.32 mg GAE, 1.65 ± 0.02 mg EQ, and 0.910 ± 0.01 mg of catechin equivalents/g dried extract (mg EC/g de extract) for TPC, TFC and CT, respectively. In the antioxidant potential assays, the values of the median inhibition concentration (IC50) of the AECS were determined with DPPH (0.050 mg/mL), ABTS (0.074 mg/mL), and FRAP (0.49 mg/mL). Acute toxicity testing of the AECS revealed no lethality, with a median lethal dose (LD50) value of >2 g/kg by the intragastric route. Finally, for inhibition of acute edema, the AECS decreased inflammation by 55%, similar to indomethacin (59%, p > 0.05). These results demonstrated that C. icaco seed could be considered a source of bioactive molecules for therapeutic purposes due to its antioxidant potential and anti-inflammatory activity derived from TPC, with no lethal effect from a single intragastric administration in mice.
PURPOSE: To obtain an antiplatelet and antithrombotic agent, comprising a substituted diphenylethylene derivative as an active ingredient and capable of manifesting excellent suppressing actions on platelet aggregation. CONSTITUTION: This agent comprises a compound of formula I [R1 and R<2> are each H, OH or a lower alkoxy; X is H, a cyano, etc., Y is a group of formula II (R<4> and R<5> are each H, a lower alkyl, arylalkyl or a heteroarylalkyl)] or its salt as an active ingredient. N-Benzyl-3,3-bis-(4-methoxyphenyl)acrylamide is exemplified as the compound of formula I. The agent is effective in treating or preventing cerebral angiopathy, postoperative thrombosis and embolus caused by vascular surgery and extracorporeal blood circulation, bloodstream disorder, ischemic cardiopathy, etc., and prevention of relapse of the diseases, improvement, etc., in prognosis. The daily dose thereof is 0.1-300mg for an adult. The compound of formula I can be obtained by reacting a carboxylic acid or its reactive acid derivative with an amine and amidating the carboxylic acid, etc.
Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h. Patients will be randomized to receive dexmedetomidine intravenously at rates of 0.2-1.4 μg/kg/h and 0.3-4 mg/kg/h for 2 days, respectively, to maintain the Richmond Agitation-Sedation Scale (RASS) within the range of +1 to -2.
Retinal Changes in Rats

Pathologic changes (degeneration/atrophy) were observed in the retinas of albino rats in the 2-year carcinogenicity study with citalopram. There was an increase in both incidence and severity of retinal pathology in both male and female rats receiving 80 mg/kg/day (13 times the maximum recommended daily human dose of 60 mg on a mg/m2 basis). Similar findings were not present in rats receiving 24 mg/kg/day for two years, in mice treated for 18 months at doses up to 240 mg/kg/day, or in dogs treated for one year at doses up to 20 mg/kg/day (4, 20, and 10 times, respectively, the maximum recommended daily human dose on a mg/m2 basis).

Additional studies to investigate the mechanism for this pathology have not been performed, and the potential significance of this effect in humans has not been established.

Cardiovascular Changes in Dogs

In a one-year toxicology study, 5 of 10 beagle dogs receiving oral doses of 8 mg/kg/day (4 times the maximum recommended daily human dose of 60 mg on a mg/m2 basis) died suddenly between weeks 17 and 31 following initiation of treatment. Although appropriate data from that study are not available to directly compare plasma levels of citalopram (CT) and its metabolites, demethylcitalopram (DCT) and didemethylcitalopram (DDCT), to levels that have been achieved in humans, pharmacokinetic data indicate that the relative dog-to-human exposure was greater for the metabolites than for citalopram. Sudden deaths were not observed in rats at doses up to 120 mg/kg/day, which produced plasma levels of CT, DCT, and DDCT similar to those observed in dogs at doses of 8 mg/kg/day. A subsequent intravenous dosing study demonstrated that in beagle dogs, DDCT caused QT prolongation, a known risk factor for the observed outcome in dogs. This effect occurred in dogs at doses producing peak DDCT plasma levels of 810 to 3250 nM (39-155 times the mean steady state DDCT plasma level measured at the maximum recommended human daily dose of 60 mg). In dogs, peak DDCT plasma concentrations are approximately equal to peak CT plasma concentrations, whereas in humans, steady state DDCT plasma concentrations are less than 10% of steady state CT plasma concentrations. Assays of DDCT plasma concentrations in 2020 citalopram-treated individuals demonstrated that DDCT levels rarely exceeded 70 nM; the highest measured level of DDCT in human overdose was 138 nM. While DDCT is ordinarily present in humans at lower levels than in dogs, it is unknown whether there are individuals who may achieve higher DDCT levels. The possibility that DCT, a principal metabolite in humans, may prolong the QT interval in dogs has not been directly examined because DCT is rapidly converted to DDCT in that species.
Dabigatran etexilate administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.
The invention provides a kind of fast and the method for health by shell terrapin, unedible, change over and possess tortoise shell powder mixture useful taste and attractive smell, edible and extremely valuable fermentation. The present invention has retained turtle shell nutrition to greatest extent, and any stimulation that the tortoise shell powder of being manufactured by conventional method is produced reduces to minimum. In addition, the present invention has strengthened digesting and assimilating of described powder, thereby effectively improves people's health and appearance. Not yet observe any passive side effect of this product. The invention provides the various steps of the positive benefits that strengthens described powder. The present invention has broken traditional tortoise shell powder to deficiency-cold in spleen and stomach, taboo cold and that forbid without hot person.
Patients received Ingaron 500,000 IU subcutaneously once a day, every other day. The course of treatment is 7 injections. The first injection was given on the first day of active therapy. Subsequent injections were given every other day. The period of active therapy was 14 days.
Clinical studies of quinapril hydrochloride did not include sufficient numbers of subjects aged 65 andover to determine whether they respond differently from younger subjects. Other reported clinicalexperience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low endof the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function,and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to thisdrug may be greater in patients with impaired renal function. Because elderly patients are more likelyto have decreased renal function, care should be taken in dose selection, and it may be useful tomonitor renal function.

Elderly patients exhibited increased area under the plasma concentration time curve and peak levelsfor quinaprilat compared to values observed in younger patients; this appeared to relate todecreased renal function rather than to age itself.
PURPOSE: A refrigerant composition containing a solvent and Paullinia cupana seed extract is provided to enhance concentration and to feel fresh. CONSTITUTION: A refrigerant composition contains: 50-80 wt% of a solvent; 10-20 wt% of skin conditioning agent containing Paullinia cupana seed extract; and 0.1-2 wt% of methyl lactate. The solvent is purified water or alcohol. The refrigerant composition further contains a moisturing agent, thickening agent, pH adjusting agent, or emulsifier. The moisturizing agent contains propylene glycol or glycerine. The thickening agent contains a carbomer. The pH adjusting agent contains triethanol amine. The emulsifier contains PEG-60 hydrogenated castor oil.
Venetoclax weight-adjusted doses administered orally every day (QD) starting on Day 1 + navitoclax various, weight-adjusted doses administered orally QD starting on Day 3 + chemotherapy (peg-asparaginase \[or any other forms of asparaginase\], vincristine, dexamethasone) and tyrosine kinase inhibitor \[TKI, if applicable\]). This regimen and any of its components may be delayed, reduced or omitted at the discretion of the Investigator.
Placebo taken daily orally for 12 months of treatment followed by 6 months washout. The trial will last 18 month in duration.
The observed incidence of anti-drug antibody (ADA, including neutralizing antibody) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of daratumumab or of other daratumumab products.

With the median DARZALEX FASPRO treatment ranging from 6.5 to 35.9 months across 7 clinical trials of patients with multiple myeloma and light chain (AL) amyloidosis treated with DARZALEX as monotherapy or as combination therapies, the incidence of anti-daratumumab antibody development was 0.6% (7/1,200) and 6 patients tested positive for neutralizing antibodies. Because of the low occurrence of anti-daratumumab antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of daratumumab products is unknown.

With the median DARZALEX FASPRO treatment ranging from 6.5 to 35.9 months across 7 clinical trials of patients with multiple myeloma and light chain (AL) amyloidosis treated with DARZALEX as monotherapy or as combination therapies, the incidence of anti-rHuPH20 antibody development was 8.9% (106/1,193) and 1 patient tested positive for neutralizing antibodies. There was no identified clinically significant effect of anti-rHuPH20 antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of daratumumab products.
Apparatus and associated methods relate to configuring secure access to a patient's stored health record data, in response to receiving the patient's consent to a health record data access request, and providing the secure access to a specific user at a location and time related to the request. The access request may be received from a provider. The provider may be a doctor. Secure access by a specific user to a discrete health record data field may be configured, granted, or revoked based on patient consent status, permitting the patient selective control over access to their personal health record data. Access encryption parameters distinct from the storage encryption parameters securing the stored health record may be configured to permit specific user access to a specific data field. The access encryption parameters may be revoked by the patient withdrawing consent, permitting the patient to assert ownership control of their health records.
Adult   
The usual adult oral dosage is 2 to 3 tablespoonfuls (30 to 45 mL, containing 20 g to 30 g of lactulose) three or four times daily. The dosage may be adjusted every day or two to produce 2 or 3 soft stools daily. 

Pediatric

Very little information on the use of lactulose in young children and adolescents has been recorded. As with adults, the subjective goal in proper treatment is to produce 2 to 3 soft stools daily. On the basis of information available, the recommended initial daily oral dose in infants is 2.5 to 10 mL in divided doses. For older children and adolescents, the total daily dose is 40 to 90 mL. If the initial dose causes diarrhea, the dose should be reduced immediately. If diarrhea persists, lactulose should be discontinued.   
Note: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water or milk.
The present invention discloses a recipe of medicinal toothpaste for tooth fastness. The toothpaste has a conventional toothpaste substrate; besides, the toothpaste mainly comprises the minimum 30% of the weight proportion of Chinese medicine portion composed of halite, hydrated gypsum, psoralea, mint, eclipta alba, asarum, parsnip, pepper, raw rhubarb, Chinese angelica, angelica dahurica and Chinese chive seeds. By using the present invention, the reconstruction function of dental pulp can be sufficiently activated. Teeth can basically obtain sufficient nutrition for solving the chronic diseases of tooth looseness and dentin fragility. The aims and the purposes of the present invention are to make movable teeth consolidated, make crisp teeth hard, not drop to oldness by continuous use, and eliminate tooth diseases. Proved by an experiment, by using the toothpaste of the present invention, the efficiency of consolidating the teeth, resisting bacteria, removing inflammation, resisting tooth ageing, killing insects, treating canker, clearing physiological fire, improving vision, etc. can be realized; the present invention can also enhance the immunity of dental organisms.
The rapid spread of the novel coronavirus disease-19 (COVID-19) pandemic has led clinicians to new and alternative methods and led the way for various practice strategies. Telehealth applications enable health professionals to transfer information, education, and training for health consumers via the Internet and telecommunication. Telehealth applications and remote assessment applications are technology and services that can be used during the COVID-19 pandemic process. In addition, practical applications can be made with the help of telephone and video in a guideline published concerning remote health applications.

The advantages of participation in exercise programs include improvements in physical performance, aerobic endurance, self-efficacy for exercise, self-assessed health, and pain relief. The COVID-19 pandemic has induced extensive disruptions to global health systems and accelerated the shift to remotely accessible counseling and home-based rehabilitation. Implementing remotely monitored exercise interventions has the advantages of greater access and accessibility and overcoming known barriers to face-to-face supervised exercise. In the COVID-19 pandemic, tele-exercise, including remote delivery of exercises via video conferencing technology, has emerged as a means for community-based programs to maintain follow-up exercise sessions while adhering to physical distancing restrictions. A previous investigation indicated that tele-yoga exercise sessions were feasible and acceptable in older adults. Social isolation, which required attention and practice during the COVID-19 pandemic, causes significant changes that negatively affect public health and physical activity levels. In the COVID-19 pandemic, remote exercise implementation methods mainly focused on patients with chronic diseases or the older population.

People who are not regularly active and have no contraindications are recommended to start and gradually increase their physical activity level. The World Health Organization guidelines for adults indicate that aerobic and muscle-strengthening physical activity exercises are based on solid evidence. Additionally, there needs to be randomized controlled studies in the literature regarding online physical exercise during COVID-19. Therefore, it is curious to evaluate the physical activity level and physical performance in adults during the COVID-19 pandemic and how exercise interventions will affect them. In this study, we aimed to examine the effect of online exercise training on physical performance and health-related quality of life (HRQoL) in non-diagnosed COVID-19 adults during the pandemic. As a hypothesis in our study, we hypothesized that four-week online exercise training would improve physical performance and HRQoL compared to the control group.
Peripheral neuropathy is a disorder of the peripheral nerves-the motor, sensory and autonomic nerves that connect the spinal cord to muscles, skin and internal organs. It usually affects the hands and feet, causing weakness, numbness, tingling and pain. Peripheral neuropathy's course is variable; it can come and go, slowly progressing over many years, or it can become severe and debilitating. Peripheral neuropathy is common and it is estimated that upwards of 20 million Americans suffer from this illness. It can occur at any age, but is more common among elderly patients. In l999, a survey found that 8-9% of Medicare recipients have peripheral neuropathy as their primary or secondary diagnosis and the annual cost to Medicare exceeds $3.5 billion. Approximately 30% of peripheral neuropathy cases are linked to diabetes. Other common causes of neuropathy include autoimmune disorders, tumors, hereditary conditions, nutritional imbalances, infections or toxins. Another 30% of peripheral neuropathies are termed "idiopathic" when the cause is unknown. Pain in particular is a complex process initiated by pain-inducing or noxious stimuli interacting with pain receptors (nociceptors) which triggers a series of action potentials that are transmitted by neurotransmitters from peripheral afferent neurons to the spinal cord and higher nerve centers in the brain.

The study intervention is classified as a medical food that must be used under the active or ongoing supervision of a physician. Medical foods are developed to address the different or altered physiologic requirements that may exist for individuals with distinctive nutritional needs arising from metabolic disorders, chronic diseases, injuries, premature birth associated with inflammation and other medical conditions, as well as from pharmaceutical therapies. All of the ingredients included in the study intervention are classified as generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA). To qualify for GRAS status, a substance that is added to a food, including a medical food, has to be supported by data demonstrating that it is safe when consumed in amounts from these foods, as they are typically ingested or prescribed.

The study intervention is a proprietary blend of amino acids and antioxidants designed to target the cellular processes involved in the management of peripheral neuropathy symptoms. All of the ingredients are supplied in small milligram quantities which allows for safe and flexible dosing.
Contingency management (CM), an evidence-based strategy that utilizes a reward-based system as positive reinforcement, has been most robustly studied in the outpatient setting, but also has the potential to improve hospital care for patients with stimulant use disorder. The hospital is a challenging environment for people who use drugs. Conflicts with staff often result from in-hospital substance use, prolonged time off the unit, and missing medications, leading to negative health outcomes and re-admissions. By relying on positive rewards to encourage positive health behaviors, CM has the potential to improve staff-patient relationships, healthcare engagement, and reduce substance use in the hospital. Stimulant use disorder is especially difficult to address in the hospital due to a lack of medications that can support cravings and withdrawal symptoms. However, little is known about CM implementation in hospitals and the hospital setting may introduce unique challenges.

The objective of this study is to adapt an outpatient mobile app-based CM intervention to the hospital setting to understand the feasibility and acceptability of a hospital-based CM intervention to improve health outcomes in hospitalized patients with substance use disorders. We'll achieve this objective through following specific aims: Aim 1: Identify adaptations needed to implement an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with substance use disorders. Aim 2: Determine the feasibility, including facilitators and barriers, of implementing a mobile app-based CM intervention in the hospital setting. Aim 3: Assess the acceptability of a mobile app-based hospital-based CM intervention to patients and staff.
Aspirin-exacerbated respiratory disease (AERD) is clinically diagnosed in patients who suffer from allergy to aspirin, asthma, nasal polyps, and chronic sinusitis. Patients with AERD are often resistant to medical management of nasal polyps, and require multiple endoscopic sinus surgeries to manage recurrences of nasal polyps. Control of AERD can be obtained through aspirin desensitization, which consists of taking aspirin every day. However, there are substantial risks and adverse side effects to taking moderate amounts of aspirin daily. Furthermore, patients experience progressively worsening nasal and respiratory disease even with complete avoidance of aspirin and other NSAIDs.

The active and major component in aspirin/NSAIDs is salicylate, which is also found naturally in some foods. Diet modification is a cost-effective intervention that has the potential to provide long-term remission of AERD. Our study will evaluate whether a low salicylate diet, which is a more cost effective and benign intervention with minimal risks, will improve nasal, sinus or respiratory symptoms, such as congestion, sinusitis, smell, or asthma.
The RI-AIR ACIP is community-based; it addresses community needs and gaps in care by: 1) enhancing asthma outcomes with services tailored to the child's level of asthma risk, 2) decreasing family burden by delivering services in homes and the local community, 3) enhancing communication between school, HCPs, and family, and 4) utilizing the RI-AIR Information Data System (IDS) to integrate data sources and generate a tailored referral. This study uses a randomized, stepped wedge trial (SWT) design to evaluate the effectiveness of the RI-AIR ACIP at both the individual and community levels. In an SWT, groups of individuals receive the intervention at different time points, the order in which they receive the treatment is randomized, and data are collected from groups over time.

In this study, groups will be randomized at the community level. Selected high risk communities are geographic school catchment areas with the highest asthma utilization rates. High-risk areas will be randomly allocated to the "Step," or year of active trial using a random numbers table. Thus, the year each catchment area receives intervention (i.e., participates in the active trial phase) will be randomized, and all families in this SWT will participate in both control (standard care) and intervention (active trial). This SWT design allows us to evaluate both individual-level outcomes as well as community-specific outcomes. During the active trial phase, families of children with asthma within the randomly selected communities will receive an asthma intervention. Families of children with asthma will be assigned to an intervention based on the child's level of asthma control. Individual-level data will be assessed over the course of the year of the active trial phase, while community-level data will be assessed annually over the study period.